It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements.

Pandemic recovery stocks like CTD and sports betting tech Blubet shone, while COVID play JB Hi-Fi continues to show growth.

Here’s some of the reports which have caught our eye today.


Corporate Travel Management (ASX:CTD)

CTD has built on its strong momentum, with revenue of $563m; underlying EBITDA $143m, and profit before tax of $102m for Q4.

CTD says its business is recovering faster than the market, as it wins more market share.

The company finished the quarter with $127m corporate cash and zero debt.

CTD has also reinstated its dividends, declaring a 5c final dividend (unfranked) paid with future intention to pay 50% of NPAT.

Bluebet (ASX:BBT)

Bluebet’s turnover for the quarter was up 5.6% to $133 million, driven by strong growth in sports and mobile channels.

The company continues to gain market share, with active customers up 40.1% to 54,920 despite cycling over strong customer acquisitions during COVID lockdowns.

Net win margin remains above 10%, despite increased promotional spend relating to the NRL and AFL finals.

Cost per FTD (CFTD) was $405 or 2.5x Annual Customer Value, which continues to provide attractive returns on marketing investment to acquire quality customers.

During the quarter, Bluebet released the Stat Wars product in Australia, and is working towards launching ClutchBet in Colorado, Louisiana and Indiana.


JB HI-Fi reported the following quick update in its Q1 results today. The results were mostly down from the pcp.

– Total sales growth for JB HI-FI Australia was 14.6% (Q1 FY22: -7.5%) with comparable sales growth of 14.2% (Q1 FY22: -7.9%)

– Total sales growth for JB HI-FI New Zealand was 27.7% (Q1 FY22: -6.4%) with comparable sales growth of 27.7% (Q1 FY22: -6.4%)

– Total sales growth for The Good Guys was 12.3% (Q1 FY22: -5.6%) with comparable sales growth of 12.3% (Q1 FY22: -6.1%). (ASX:RNT)

RNT delivered quarterly revenue of $825k, 2% lower than the pcp.

The core portal has recorded 9th straight EBITDA positive quarter.

At the end of the quarter, the company has $1.3m in cash on hand, plus $0.7m R&D refund claim lodged.

Dimerix (ASX:DXB)

Dimerix ended the quarter with cash of $6.1 million, with net operating cash outflows for the period of $3.5 million.

Cash outflow for the period predominately related to Clinical and CMC costs related to the Phase 3 FSGS Study.

The Phase 3 FSGS ACTION3 clinical trial Part 1 has recruited 48 patients (67% completed) during the quarter, while the CLARITY 2.0 COVID-19 study has concluded recruitment.

In another study, the DMX-700 trial has shown significant 80% reduction in lung injury, and a new patent family application for DMX-7003 has now been submitted.

During the quarter, Dimerix presented at the BIO Europe International Partnering Convention.

The company’s net operating cash flow for the September quarter was -$3.5 million.

Pro forma cash position was around $12 million, including R&D Tax incentive refund of $6million received post quarter end.

Race Oncology (ASX:RAC)

Q1 FY23 was highlighted by the Race team’s development of an improved and novel formulation of the company’s lead drug, Zantrene, which enables peripheral intravenous (IV) delivery.

A second highlight was the initiation of the new m6A RNA methylation pathway-targeted drug discovery program, in collaboration with Professor Martin Scanlon, through the Monash Fragment Platform.

Race has also continued to progress its Three Pillar Strategy, capitalising on the opportunity of RNA therapeutics in cancer and cardioprotection provided by Zantrene.

During the quarter, the company’s on-market buyback continued, with an additional $1.2 million invested through Q1 FY 2023.

Plenti Group (ASX:PLT)

Plenti’s loan portfolio increased to $1.55 billion, 69% above pcp and 7% ($107 million) above prior quarter.

Revenue for the quarter was $33.3 million, 64% above pcp and 9% above prior quarter.

Plenti saw strong quarterly loan originations of $269 million maintained despite material customer rate increases, with record electric vehicle and renewable energy lending

The company also reported exceptional credit performance with annualised net credit losses of 69 basis points and 90+ day arrears reducing to 28 basis points at period end.

Plenti’s warehouse loan funding capacity increased by $250 million, providing headroom of ~$340 million.

There is an increased proportion of loans funded by retail investors via Plenti Lending Platform, a unique funding platform with 25,000+ investors, providing material funding cost, depth and flexibility benefits.

Plenti says its medium focus is to drive profitability from economic benefits of scale.

Humm (ASX:HUM)

The BNPL play reported first quarter volume of $988.2m, up 29% on pcp.

Consumer finance volume was $601.7m, up 8% on pcp.

BNPL big ticket volume rose 8% with BNPL small ticket down 11%, a result of planned product closures.




Share prices today:




At Stockhead we tell it like it is. While Dimerix, Race Oncology and Plenty are Stockhead advertiser, they did not sponsor this article.